18FDG PET in oncology: The best and the worst (Review) (original) (raw)
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials
Lalitha Shankar
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006
View PDFchevron_right
Kostakoglu, L. & Goldsmith, S. J. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J. Nucl. Med. 44, 224-239
Lale Kostakoglu
Journal of Nuclear Medicine
View PDFchevron_right
Tumor-specific positron emission tomography imaging in patients:[18F] fluorodeoxyglucose and beyond
Mark Muzi
Clinical Cancer …, 2007
View PDFchevron_right
Appropriateness criteria of FDG PET/CT in oncology
Venkatesh Rangarajan
Indian Journal of Radiology and Imaging, 2015
View PDFchevron_right
Positron Emission Tomography (PET) in Oncology
Anna Borra
Cancers, 2014
View PDFchevron_right
Quantitative FDG PET Assessment for Oncology Therapy
Nagara Tamaki
Cancers, 2021
View PDFchevron_right
18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma
Lale Kostakoglu
2000
View PDFchevron_right
Can the Efficacy of [18F]FDG-PET/CT in Clinical Oncology Be Enhanced by Screening Biomolecular Profiles?
Vinod Malik
Pharmaceuticals
View PDFchevron_right
The role of 18F-FDG PET in oncology: clinical and resource implications
AVIRAL SINGH
Nuclear medicine review. Central & Eastern Europe, 2006
View PDFchevron_right
FDG PET/CT in oncology: "raising the bar
Andy Scarsbrook
Clinical radiology, 2010
View PDFchevron_right
Four-dimensional quantitative analysis using FDG-PET in clinical oncology
Nagara Tamaki
Japanese Journal of Radiology
View PDFchevron_right
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Lalitha Shankar
Clinical Cancer Research, 2005
View PDFchevron_right
Clinical Value of Combined Positron Emission Tomography/Computed Tomography Imaging in the Interpretation of 2-Deoxy-2-[F-18]fluoro- d -glucose–Positron Emission Tomography Studies in Cancer Patients
Heiko Schoder
Molecular Imaging and Biology, 2005
View PDFchevron_right
Appropriate use of positron emission tomography with [18F]fluorodeoxyglucose for staging of oncology patients
Luca Tagliabue
European Journal of Internal Medicine, 2014
View PDFchevron_right
[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Imaging in Oncology: Initial Staging and Evaluation of Cancer Therapy
Magdalena Kostkiewicz
Medical Principles and Practice, 2013
View PDFchevron_right
Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer
Eric Visser, Paul Krabbe
Journal of Nuclear Medicine, 2007
View PDFchevron_right
Procedure Guideline for Tumor Imaging with 18 F-FDG PET/CT 1.0*
Scott Holbrook
2010
View PDFchevron_right
FDG-PET Determination of Metabolically Active Tumor Volume and Comparison with CT
Ken Zasadny
Clinical Positron Imaging, 1998
View PDFchevron_right
A new dimension of FDG-PET interpretation: assessment of tumor biology
Drew Torigian, Babak Saboury
European Journal of Nuclear Medicine and Molecular Imaging, 2011
View PDFchevron_right
Applications of 18(F) FDG PET/CT in oncology
ahmad saad
2015
View PDFchevron_right
FDG-PET imaging in hematological malignancies
Laia Valls
Blood Reviews, 2016
View PDFchevron_right
Positron emission tomography in oncology: General acceptance of its role is overdue
Lamk Lamki
Cancer, 1996
View PDFchevron_right
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer
Chin-tu Chen
European Journal of Nuclear Medicine and Molecular Imaging, 2012
View PDFchevron_right
Recommendations on the Use of 18F-FDG PET in Oncology
James Fletcher
2008
View PDFchevron_right